Tiagabine and exacerbation of essential tremor.
Zesiewicz, TA, CL Ward, and RA Hauser. 2007. “Tiagabine and Exacerbation of Essential Tremor.”. Mov Disord.
Search
Search results
818 results found
Role of the pharmacist in the effective management of wearing-off in Parkinson’s disease.
Simonson, W, RA Hauser, and AH Shapira. 2007. “Role of the Pharmacist in the Effective Management of Wearing-off in Parkinson’s Disease.”. Ann Pharmacother.
Ten-year follow-up of Parkinson’s disease patients randomized to initial therapy with ropinirole or levodopa.
Hauser, RA, O Rascol, AD Korczyn, Jon Stoessl, RL Watts, W Poewe, PP De Deyn, and AE Lang. 2007. “Ten-Year Follow-up of Parkinson’s Disease Patients Randomized to Initial Therapy With Ropinirole or Levodopa.”. Mov Disord.
ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
Olanow, CW, O Rascol, RA Hauser, PD Feigin, J Jankovic, A Lang, W Langston, et al. 2009. “ADAGIO Study Investigators. A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson’s Disease.”. N Engl J Med.
Placebo response in Parkinson’s disease: Comparisons among 11 trials covering medical and surgical interventions
Goetz, CG, J Wuu, MP McDermott, CH Adler, S Fahn, CR Freed, RA Hauser, et al. 2008. “Placebo Response in Parkinson’s Disease: Comparisons Among 11 Trials Covering Medical and Surgical Interventions”. Mov Disord.
A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results
Investigators, The NINDS NET-PD, and RA Hauser. 2008. “A Pilot Clinical Trial of Creatine and Minocycline in Early Parkinson Disease: 18-Month Results”. Clin Neuropharmacol.
Zydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations: A 3-month, randomized, placebo-controlled study. Movement Disorders 2004;19:426-432.
Waters, CH, KD Sethi, RA Hauser, E Molho, and JM Bertoni. 2004. “Zydis Selegiline Reduces Off Time in Parkinson’s Disease Patients With Motor Fluctuations: A 3-Month, Randomized, Placebo-Controlled Study. Movement Disorders 2004;19:426-432.”. Movement Disorders.
Levodopa/carbidopa/entacapone triple combination (Stalevo). Neurology 2004;62 (Suppl 1):S64-71.
Hauser, RA. 2004. “Levodopa/Carbidopa/Entacapone Triple Combination (Stalevo). Neurology 2004;62 (Suppl 1):S64-71.”. Neurology.
Factors associated with the development of motor fluctuations and dyskinesias in Parkinson’s disease.
Hauser, RA, MP McDermott, S Messing, and Parkinson Study Group. 2006. “Factors Associated With the Development of Motor Fluctuations and Dyskinesias in Parkinson’s Disease.”. Arch Neurol.
Nonmotor symptoms of Parkinson’s disease.
Zesiewicz, TA, KL Sullivan, and RA Hauser. 2006. “Nonmotor Symptoms of Parkinson’s Disease.”. Expert Rev Neurother.